InflaRx N.V. (IFRX): Price and Financial Metrics


InflaRx N.V. (IFRX): $2.17

0.03 (+1.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IFRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IFRX Stock Price Chart Interactive Chart >

Price chart for IFRX

IFRX Price/Volume Stats

Current price $2.17 52-week high $3.81
Prev. close $2.14 52-week low $0.78
Day low $2.12 Volume 64,873
Day high $2.28 Avg. volume 89,655
50-day MA $2.53 Dividend yield N/A
200-day MA $2.17 Market Cap 95.92M

InflaRx N.V. (IFRX) Company Bio


Fireman B.V. (InflaRx) operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. The company is based in Jena, Germany.


IFRX Latest News Stream


Event/Time News Detail
Loading, please wait...

IFRX Latest Social Stream


Loading social stream, please wait...

View Full IFRX Social Stream

Latest IFRX News From Around the Web

Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patientsFDA review of application for emergency use authorization (EUA) of vilobelimab for the treatment of critically ill COVID-19 patients ongoing InflaRx’s management team to host investor and business meetings during JPM Week, January 9 – 12, 2023 in San Franci

Yahoo | January 5, 2023

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in ChinaSTS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s technology in-licensed by STSInflaRx will receive 10% royalties on net sales of BDB-001 for the treatment of COVID-19 in ChinaSTS to make an additional USD 2.5 million investment in InflaRx at a price of USD

Yahoo | December 21, 2022

Raymond James Reaffirms Their Buy Rating on InflaRx (IFRX)

Raymond James analyst Steven Seedhouse maintained a Buy rating on InflaRx (IFRX - Research Report) today and set a price target of $8.00. The company's shares opened today at $2.70.Seedhouse covers the Healthcare sector, focusing on stocks such as Intercept Pharma, Rocket Pharmaceuticals, and Intellia Therapeutics. According to TipRanks, Seedhouse has an average return of 3.8% and a 42.48% success rate on recommended stocks. InflaRx has an analyst consensus of Moderate Buy, with a price target consensus of $8.00, representing a 196.30% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.

Ryan Adist on TipRanks | November 10, 2022

InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904

Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and pharmacokinetics in healthy volunteersFuture development in complement-mediated chronic diseases JENA, Germany, Nov. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today a

Yahoo | November 9, 2022

InflaRx Reports Third Quarter 2022 Financial & Operating Results

Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S. Food and Drug Administration (FDA)PANAMO Phase III study results in severe COVID-19 published in peer-reviewed journal, The Lancet Respiratory Medicine Fast Track designation granted for the treatment of pyoderma gangrenosum by FDACash, cash equivalents and marketable securities of €93.2 million, e

Yahoo | November 9, 2022

Read More 'IFRX' Stories Here

IFRX Price Returns

1-mo -30.00%
3-mo -17.49%
6-mo -29.32%
1-year -39.22%
3-year -32.82%
5-year -90.59%
YTD -30.00%
2022 -34.87%
2021 -5.37%
2020 27.02%
2019 -89.11%
2018 73.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6132 seconds.